Krystal Biotech, Inc. is a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented herpes simplex virus 1 (HSV 1) based gene therapy platform to create vectors that deliver therapeutic transgenes to cells in multiple organ systems, enabling durable, redosable expression of therapeutic proteins. Its lead product, VYJUVEK (beremagene geperpavec‑svdt), is approved in the United States, the European Union, and Japan for the treatment of dystrophic epidermolysis bullosa (DEB), a rare monogenic skin disease caused by mutations in the COL7A1 gene. Beyond VYJUVEK, Krystal Biotech, Inc. maintains a diverse pipeline that includes inhaled gene therapies for cystic fibrosis (KB407) and alpha 1 antitrypsin deficiency (KB408), ophthalmic formulations for neurotrophic keratitis (KB801) and ocular complications of DEB (KB803), topical agents for epidermolysis bullosa related skin disease (KB111) and Hailey Hailey disease, immunotherapeutic candidates for solid tumors (KB707), and aesthetic product candidates targeting skin aging (KB301, KB304). The firm operates two in house commercial scale CGMP manufacturing facilities, ANCORIS and ASTRA, which support production of VYJUVEK and its pipeline candidates, enabling end to end control of the supply chain from raw material to patient delivery.

Krystal Biotech, Inc. generates revenue primarily from the sale of its commercial product VYJUVEK, which is marketed directly in the United States, major European markets, and Japan and through a network of specialty distributors in other territories. The company reported cumulative net product revenue of $730.3 million since the U. S. launch of VYJUVEK in 2023, with additional revenue streams limited to occasional gains such as the sale of a Rare Pediatric Disease Priority Review Voucher for $100 million in 2023. Product sales remain the core of the company’s income, and revenue growth is driven by expanding geographic availability, increasing patient identification, and ongoing pricing negotiations in European countries such as Germany, France, and Italy. No recurring licensing or collaboration revenue is disclosed in the filing.

Krystal Biotech, Inc. holds a pioneering position as the developer of the first corrective therapy approved worldwide for dystrophic epidermolysis bullosa, distinguishing itself from palliative treatments such as Chiesi Farmaceutici’s Filsuvez and autologous gene therapy approaches pursued by Abeona Therapeutics’ Zevaskyn and Castle Creek Biosciences’ grafting technology. The company’s HSV1 based platform provides competitive advantages that include a large payload capacity of up to 35 kilobases, non integrating episomal persistence that reduces genotoxic risk, high transduction efficiency in epithelial tissues, and the capacity for repeat, non invasive administration without requiring hospitalization. These attributes enable Krystal Biotech, Inc. to address monogenic diseases across the skin, lung, and eye with a single versatile vector system. In respiratory therapeutics, its inhaled candidates KB407 and KB408 compete with nucleic acid programs from Vertex Pharmaceuticals, ReCode Therapeutics, and 4D Molecular Therapeutics, while its ophthalmic asset KB801 faces competition from recombinant nerve growth factor eye drops such as Dompé farmaceutici’s Oxervate. In oncology, KB707’s immunotherapy approach contends with established checkpoint inhibitor and CAR T therapies from Merck, Bristol Myers Squibb, and Johnson & Johnson. The firm’s internal CGMP manufacturing capability further strengthens its position by reducing reliance on third party manufacturers and protecting proprietary processes.

Krystal Biotech, Inc. serves patients diagnosed with dystrophic epidermolysis bullosa, a population estimated at approximately 3,000 individuals in the United States and over 9,000 worldwide, as well as their caregivers and licensed healthcare professionals who administer VYJUVEK in clinics, hospitals, or at home under physician guidance. The product is distributed through a growing network of specialty distributors covering Central and Eastern Europe, the Middle East, Turkey, and Israel, with additional partnerships under discussion for other Western European markets. In its core markets of the United States, Europe, and Japan, the company engages directly with healthcare providers, payors, and specialty pharmacies to secure reimbursement and facilitate patient access to VYJUVEK. While the filing does not name individual distributor or hospital customers, it indicates that the commercial strategy targets treating physicians, dermatology centers, and specialized EB clinics that manage the disease’s complex wound care needs.